Tad Koch

  • Professor Emeritus
  • CHEMISTRY

Education

Ph.D.: Iowa State University, 1968

Areas of Expertise

Bio-Organic & Bio-Inorganic, Nucleic Acids, Chemical Biology/Genetics

Member of the University of Colorado Cancer Center and the Graduate Faculty of the School of Pharmacy, University of Colorado Health Sciences Center

Tamura, R.; Balabanova, A.; Frakes, S.A.; Bargmann, A.; Grimm, J.; Koch, T.H.; Yin, H. J.; Photoactivatable Prodrug of Doxazolidine Targeting Exosomes, J. Med. Chem. 2019, 62, 1959鈥1970.

Ganesh, A.N.; Aman, A.; Logie, J.; Barthel, B.L.; Cogan, P.; Al-awar, R.; Koch, T.H.; Shoichet, B.K.; Shoichdet, M.S,; Colloidal Drug Aggregate Stability in High Serum Conditions and Pharmacokinetic Consequences, ACS Chem. Biol. 2019, 14, 751-757.

Barthel, B. L.; Mooz, E. L.; Wiener, L. E.; Koch, G. G.; Koch, T. H. Correlation of in Situ Oxazolidine Formation with Highly Synergistic Cytotoxicity and DNA Cross-Linking in Cancer Cells from Combinations of Doxorubicin and Formaldehyde. J. Med. Chem., 59, 2205-2221 (2016).

Barthel, B.L.; Rudnicki, D.L.; Kirby, T.P.; Colvin, S.M.; Burkhart, D.J.; Koch, T.H.; Synthesis and Biological Characterization of Protease-Activated Prodrugs of Doxazolidine, J. Med. Chem., 55, 6595-6607 (2012).

Barthel, B.L.; Zhang, Z.; Rudnicki, D.L.; Coldren, C.D.; Polinkovsky, M.; Sun, H.; Koch, G.G.; Chan, D.C.F.; Koch, T.H. "Preclinical efficacy of a carboxylesterase 2-activated prodrug of doxazolidine" J. Med. Chem. 52, 7678-7688 (2009).

Spencer, D.M.; Bilardi, R.A.; Koch, T.H.; Post, G.C.; Nafie, J.W.; Kimura, K.I.; Cutts, S.M.; Phillips, D.R. 鈥淒NA repair in response to anthracycline-DNA adducts: A role for both homologuous recombination and nucleotide excision repair鈥 Mutat. Res., 638, 110-121 (2008).

Koch, T.H.; Barthel, B.L.; Kalet, B.T.; Rudnicki, D.L.; Post, G.C.; Burkhart, D.J. 鈥淎nthracycline-formaldehyde conjugates and their targeted prodrugs鈥 In Anthracylines: Chemistry and Biology, Topics in Current Chemistry (Krohn, K., ed.), Springer, Heidelberg, 283, 141-170 (2008).

Barthel, B.L.; Torres, R.C.; Hyatt, J.L.; Edwards, C.C.; Hatfield, M.J.; Potter, P.M.; Koch, T.H. 鈥淚dentification of human intestinal carboxylesterase as the primary enzyme for activation of a doxazolidine carbamate prodrug鈥 J. Med. Chem. 51, 298-304 (2008).

Kalet, B.T.; McBryde, M.B.; Espinosa, J.M.; Koch, T,H. 鈥淒oxazolidine induction of apoptosis by a topoisomerase II independent mechanism鈥 J. Med. Chem. 50, 4493-4500 (2007).

Burkhart, D. J.; Barthel, B.L.; Post, G.C.; Kalet, B.T.; Nafie, J.W.; Shoemaker, R.K.; Koch, T.H. "Design, synthesis, and preliminary evaluation of doxazolidine carbamates as prodrugs activated by carboxylesterases" J. Med. Chem. 49, 7002-7012 (2006).

Post, G.C.; Barthel, B.L.; Burkhart, D.J.; Hagadorn, J.R.; Koch, T.H. 鈥淒oxazolidine, a Proposed Active Metabolite of Doxorubicin that Cross-links DNA鈥 J. Med. Chem. 2005, 48, 7648-7657.